he was unable to walk or use his hands.; Pain in his teeth; slurring his words; Tingling starting in the fingers and toes then overnight spread to his hands/arms/legs and mouth.; Tingling starting in the fingers and toes then overnight spread to his hands/arms/legs and mouth/tingling throughout his mouth; numbness starting in the fingers and toes then overnight spread to his hands/arms/legs and mouth.; numbness starting in the fingers and toes then overnight spread to his hands/arms/legs and mouth.; This spontaneous case was reported by a consumer and describes the occurrence of HEMIPARESIS (he was unable to walk or use his hands.) in a 63-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 037F21A and 053E21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 04-Sep-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Oct-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced HEMIPARESIS (he was unable to walk or use his hands.) (seriousness criterion medically significant), TOOTHACHE (Pain in his teeth), DYSARTHRIA (slurring his words), PARAESTHESIA (Tingling starting in the fingers and toes then overnight spread to his hands/arms/legs and mouth.), PARAESTHESIA ORAL (Tingling starting in the fingers and toes then overnight spread to his hands/arms/legs and mouth/tingling throughout his mouth), HYPOAESTHESIA (numbness starting in the fingers and toes then overnight spread to his hands/arms/legs and mouth.) and HYPOAESTHESIA ORAL (numbness starting in the fingers and toes then overnight spread to his hands/arms/legs and mouth.). At the time of the report, HEMIPARESIS (he was unable to walk or use his hands.), TOOTHACHE (Pain in his teeth), DYSARTHRIA (slurring his words), PARAESTHESIA (Tingling starting in the fingers and toes then overnight spread to his hands/arms/legs and mouth.), PARAESTHESIA ORAL (Tingling starting in the fingers and toes then overnight spread to his hands/arms/legs and mouth/tingling throughout his mouth), HYPOAESTHESIA (numbness starting in the fingers and toes then overnight spread to his hands/arms/legs and mouth.) and HYPOAESTHESIA ORAL (numbness starting in the fingers and toes then overnight spread to his hands/arms/legs and mouth.) outcome was unknown.            No concomitant medication were provided by the reporter No treatment medication were provided by the reporter The patient had Difficulty speaking due to the event Dysarthria The patient had gait inability due to the event Hemiparesis Company Comment : This case concerns a 63-year-old, male patient, with no disclosed medical history, who experienced the serious, unexpected events of dysarthria, hemiparesis, paresthesia, paresthesia oral, hypoaesthesia, hypoaesthesia oral and toothache. The events occurred  on unknown date after second dose of mRNA 1273 vaccine. The patient had tingling in his fingers and toes which spread to his extremities and mouth. He also had difficulty speaking, slurring of words and was unable to walk or use his hands. The rechallenge is not applicable as there is no information regarding a third dose. The benefit-risk relationship of mRNA 1273 vaccine is not affected by this report.   Most recent FOLLOW-UP information incorporated above includes: On 17-Nov-2021: Dosage information added for suspect.; Sender's Comments: This case concerns a 63-year-old, male patient, with no disclosed medical history, who experienced the serious, unexpected events of dysarthria, hemiparesis, paresthesia, paresthesia oral, hypoaesthesia, hypoaesthesia oral and toothache. The events occurred  on unknown date after second dose of mRNA 1273 vaccine. The patient had tingling in his fingers and toes which spread to his extremities and mouth. He also had difficulty speaking, slurring of words and was unable to walk or use his hands. The rechallenge is not applicable as there is no information regarding a third dose. The benefit-risk relationship of mRNA 1273 vaccine is not affected by this report.